- Open Access
Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion
Retrovirologyvolume 8, Article number: 99 (2011)
We recently provided evidence that HIV-1 enters HeLa-derived TZM-bl and lymphoid CEMss cells by fusing with endosomes, whereas its fusion with the plasma membrane does not proceed beyond the lipid mixing step. The mechanism of restriction of HIV-1 fusion at the cell surface and/or the factors that aid the virus entry from endosomes remain unclear.
We examined HIV-1 fusion with a panel of target cells lines and with primary CD4+ T cells. Kinetic measurements of fusion combined with time-resolved imaging of single viruses further reinforced the notion that HIV-1 enters the cells via endocytosis and fusion with endosomes. Furthermore, we attempted to deliberately redirect virus fusion to the plasma membrane, using two experimental strategies. First, the fusion reaction was synchronized by pre-incubating the viruses with cells at reduced temperature to allow CD4 and coreceptors engagement, but not the virus uptake or fusion. Subsequent shift to a physiological temperature triggered accelerated virus uptake followed by entry from endosomes, but did not permit fusion at the cell surface. Second, blocking HIV-1 endocytosis by a small-molecule dynamin inhibitor, dynasore, resulted in transfer of viral lipids to the plasma membrane without any detectable release of the viral content into the cytosol. We also found that a higher concentration of dynasore is required to block the HIV-endosome fusion compared to virus internalization.
Our results further support the notion that HIV-1 enters disparate cell types through fusion with endosomes. The block of HIV-1 fusion with the plasma membrane at a post-lipid mixing stage shows that this membrane is not conducive to fusion pore formation and/or enlargement. The ability of dynasore to interfere with the virus-endosome fusion suggests that dynamin could be involved in two distinct steps of HIV-1 entry - endocytosis and fusion within intracellular compartments.
Infection of cells by human immunodeficiency virus type 1 (HIV-1) is a multistep process beginning with the sequential binding of the gp120 subunit of the viral envelope glycoprotein (Env) to CD4 and a coreceptor CCR5 or CXCR4 [1, 2]. Interactions with CD4 and coreceptor trigger conformational changes in the transmembrane subunit of Env, gp41, which ultimately mediates membrane fusion [3, 4]. As with other viruses that do not depend on low pH for entry, HIV-1 has been widely believed to undergo fusion at the plasma membrane, whereas endocytosis has been regarded as a nonproductive pathway leading to virus degradation (for example, [5–7]). This view is based mainly on the following lines of evidence. First, HIV-1 Env mediates cell-cell fusion at neutral pH [7, 8], and the virus itself can fuse adjacent cells expressing CD4 and coreceptors [9, 10] (termed "fusion from without"). Second, HIV-1 infection is not compromised by mutations in the cytoplasmic domains of CD4 or coreceptors that severely impair their ability to undergo ligand-mediated endocytosis [5, 6, 11, 12]. Third, in contrast to HIV-1, VSV G-pseudotyped HIV particles, which constitutively enter through endocytosis, exhibit different requirements for HIV-1 accessory proteins for infection , and strikingly, fail to infect resting CD4+ T cells [14–16]. Also, the membrane transport activity of Arf6 (ADP-ribosylation factor 6) appears essential for clathrin-independent CD4/HIV-1 co-internalization and fusion, but not for fusion of VSV G pseudotypes .
The above evidence, while supporting HIV-1 fusion with the plasma membrane, are somewhat indirect and generally do not rule out the existence of an endocytic entry pathway for this virus. For instance, the lack of low pH-dependence [8, 18, 19] simply means that HIV-1 fusion is not restricted to acidic compartments. It also remains to be demonstrated that CD4 and coreceptor mutants impaired in ligand-mediated endocytosis do not co-internalize with the virus, which would allow fusion with endosomes. On the other hand, accumulating evidence support the existence of productive HIV-1 entry through endocytosis. The observation that trans-dominant negative mutants of dynamin-2 and Eps15 potently inhibit HIV-1 fusion and infection  implies that this virus relies, at least in part, on clathrin-mediated endocytosis for productive entry. Moreover, a specific small-molecule inhibitor of clathrin function interferes with HIV-1 uptake and infectivity . Finally, inhibition of dynamin GTPase activity by dynasore effectively suppressed clathrin-dependent uptake of transferrin and low density lipoprotein , as well as HIV-1 endocytosis, fusion and infectivity .
By employing non-invasive imaging technologies and functional assays, we have gained further insights into the mechanism of HIV-1 entry . First, visualization of single virus entry into cells revealed two types of fusion events - transfer of the viral lipids into the plasma membrane without the subsequent release of the viral content (hemifusion) and release of the viral content without significant dilution of the viral membrane marker, which corresponds to complete virus fusion with small intracellular compartments. Second, comparison of the rates of HIV-1 escape from a membrane-impermeable fusion inhibitor and from low temperature applied at different times during the virus entry demonstrated a delayed protection from the temperature block compared to resistance to a fusion inhibitor. Collectively, these findings imply that HIV-1 fuses with endosomes, but fails to undergo complete fusion with the plasma membrane. We also found that endosomal fusion was inhibited by a dynamin-2 inhibitor, dynasore, suggesting that dynamin is involved both in the virus uptake and in the subsequent fusion step occurring within endosomes .
The basis for HIV's strong preference for entry through endosomes is not clear. Contrary to the model proposed in , kinetic measurements of lipid mixing with the plasma membrane demonstrated that the lack of complete fusion at the cell surface was not due to the faster virus uptake which would clear the virus from the plasma membrane before it undergoes fusion. Nearly 80% of Env- and receptor-dependent lipid mixing events at the plasma membrane occurred before significant endocytosis or endosomal fusion were detected [23, 25]. Here, to gain further insight into the determinants of HIV-1 fusion, we tested whether this virus was able to fuse with the plasma membrane of distinct target cells, such as lymphoid cells and U87.CD4.CCR5 cells, which appeared to support limited fusion between immobilized viruses and the plasma membrane of detached cells . Moreover, we attempted to redirect HIV-1 fusion to the cell surface by preventing virus uptake, using endocytosis inhibitors or reduced temperature. However, these interventions did not favor complete fusion at the cell surface, in spite of the extended window of opportunity to enter from the plasma membrane. Our results thus reinforce the notion that HIV-1 enters different cell types by endocytosis and demonstrate that the failure of this virus to fuse with the plasma membrane is not due to the kinetically dominant endocytosis that removes fusogenic viruses from the cell surface. Finally, we found that dynasore blocked productive endocytosis of HIV-1 more efficiently than virus-endosome fusion, consistent with a more critical role of dynamin in endocytic vesicle formation compared to virus-endosome fusion.
A functional approach to define the virus entry pathways
We have previously designed a strategy to deduce the sites of entry for enveloped viruses that fuse in a low pH-independent manner . The progression of HIV-1 entry through endocytosis and fusion was analyzed by adding either a membrane-impermeable inhibitory C-peptide, C52L , or by lowering the temperature. The HIV-1 gp41-derived C52L binds to the complementary gp41 domain formed/exposed following the Env binding to CD4 and coreceptors, thereby preventing the formation of the final 6-helix bundle structure . Once gp41 completes folding into a stable 6-helix bundle, which occurs immediately after, but not before the fusion pore formation , fusion is no longer sensitive to C-peptide inhibition [29–31]. Therefore, C52L targets only surface-accessible viruses that have engaged CD4 or both CD4 and coreceptor, but have not progressed through the fusion step (Figure 1A). Note that binding of C-peptides to intermediate conformations of gp41 formed at the cell surface will block subsequent HIV-1 fusion with endosomal compartments. On the other hand, both cell-surface and endosomal fusion should be inhibited by low temperature (Figure 1A).
The above approach is based on the notion that endosomal fusion is usually delayed relative to the virus uptake. Thus, by comparing the rate of virus escape from a membrane-impermeable fusion inhibitor targeting cell surface-bound viruses to the rate of escape from low temperature that blocks all fusion events (referred to as a temperature block, TB), one can deduce whether the virus fuses at the plasma membrane or after entering by endocytosis . Internalized viruses are protected from the peptide inhibitor, but not from the TB until the fusion step is completed (Figure 1A). Therefore, identical rates of virus escape from a peptide inhibitor and from TB (Figure 1B, solid vs. dotted line) would be consistent with direct fusion at the plasma membrane (PM) or with endosomal fusion immediately following the virus uptake. By comparison, delayed escape from the TB (Figure 1B, dashed line) implies that fusion occurs after a considerable lag time following the virus uptake and therefore productive entry must occur from endosomal compartments. In this case, protection from a peptide inhibitor likely reflects productive virus endocytosis and not the formation of 6-helix bundles as a result of fusion with the plasma membrane.
HIV-1 exhibits strong preference for endosomal entry into engineered and natural target cells
Using the above functional strategy, we have previously found that HIV-1 enters target cells via endocytosis and fusion with endosomes . Here, to test whether endocytic entry of HIV-1 was cell type-dependent, we analyzed the kinetics of HIV-1 fusion with several engineered and natural target cells. Virus-cell fusion was examined using the β-lactamase (BlaM) assay, which measures the transfer of viral core-associated enzyme into the cytosol . HIV-1 cores pseudotyped with different HIV-1 envelope glycoproteins (Env) were bound to adherent or suspended target cells in the cold, and their fusion was initiated by shifting to 37°C. Fusion was stopped after varied times of incubation either by adding a fully inhibitory concentration of C52L or by chilling the samples (TB).
We have previously demonstrated that HXB2 (CXCR4-tropic) and JRFL (CCR5-tropic) Env-pseudotyped particles enter TZM-bl indicator cells through an endocytic pathway, as evidenced by the delayed escape from TB compared to C52L . Here we asked whether the same kinetic pattern can be observed for another CCR5-tropic HIV-1 isolate, BaL (Figure 2A). BaL-pseudotyped particles acquired resistance to C52L much earlier than to TB, implying that this Env also mediates the virus uptake and fusion with intracellular compartments. Interestingly, the respective kinetics of HXB2 and JRFL pseudovirus escape from the above inhibitors were close to those observed for BaL pseudotypes (Figure 2A). These results strengthen the argument that the tropism or the strain-specific features of HIV-1 Env does not determine the virus entry pathway in HeLa-derived target cells.
Next, we examined the sequence of steps leading to HIV-1 fusion in the U87.CD4.CCR5 cells expressing both CD4 and CCR5 . Using single virus imaging, our group has previously shown that these cells, but not HeLa- or HOS-derived target cells, supported limited content release form HIV-1 pseudoviruses immobilized on coverslips . Since in these experiments, target cells were detached from the culture plates and overlaid on immobilized viruses, we wanted to test whether HIV-1 pre-bound to adherent target cells would be able to release its content at the plasma membrane. Kinetic experiments revealed that escape of cell-bound JRFL viruses from the TB was markedly delayed compared to the acquisition of resistance to C52L (Figure 2B), suggesting that this virus entered the U87-derived cells primarily via an endocytic pathway.
We then asked whether the kinetics of HIV-1 entry and fusion with lymphoid cells would differ from those observed in engineered cell lines. In agreement with our previous results , HIV-1 entry into CEMss cells exhibited delayed resistance to TB relative to C52L (Figure 2C). A similar pattern was observed for PM1 cells (Figure 2D), whereas in Jurkat cells HIV-1 escape from TB was marginally delayed compared to the acquisition of resistance to the inhibitory peptide (Figure 2E). Finally, we compared the rates of HIV-1 escape from C52L and TB upon entry into primary CD4+ T cells. As can be seen from 2F, there was modest but significant lag between the acquisition of resistance to the inhibitory peptide and to low temperature. This result suggests that at least a fraction of fusion-competent viruses escaped from C52L by undergoing endocytosis and fusing with intracellular compartments.
Collectively, our findings imply that HIV-1 enters epithelial, glial and lymphoid cells through an endocytic route. The variable lag between the virus uptake and fusion observed for these cells highlights the role for cell type-dependent endosomal trafficking in delivering HIV-1 into fusion-permissive compartments.
Single HIV-1 tracking reveals endosomal entry and fusion with lymphoid cells
To verify HIV-1 entry through an endocytic pathway, as suggested by the BlaM assay, we imaged the fusion of single pseudoviruses with lymphoid cells. Co-labeling pseudoparticles with a small releasable viral content marker tagged with GFP and with the lipophilic dye DiD incorporated into the viral envelope allowed for pinpointing the sites of virus entry . This approach takes advantage of the tremendous difference in the surface area of the plasma membrane and an endosome, so that virus hemifusion/fusion would lead to infinite dilutions (disappearance) of the lipid marker at the plasma membrane vs. limited dilution (retention) in endosomes. The viral content release marks the pore formation that results in disappearance of punctate signal through dilution within the cytosol, irrespective of the fusion site. We have previously shown that cell surface-bound HIV-1 particles exchange lipids with the plasma membrane, but do not release their content, an outcome suggestive of a hemifusion phenotype [23, 26, 34]. Internalized virions, on the other hand, underwent full fusion with endosomes. This experimental approach has been validated using viruses known to enter cells via endocytosis .
To further confirm that HIV-1 enters lymphoid cells through an endocytic pathway, we tracked entry of single JFRL Env pseudoviruses into CEM.NKR-CCR5.Luc cells stably expressing CCR5. Virus uptake and fusion were triggered by quickly raising the temperature in the image field to 37°C (Figure 3A and 3C, time = 0 sec), as described in . Due to the limited cytoplasm around the nucleus of CEM-derived cells, it was virtually impossible to visualize the virus trafficking from the cell periphery toward the nucleus based on spatial displacement. Importantly, however, we were able to deduce the site of HIV-1 entry into these cells by monitoring the extents of dilution of viral lipid and content markers ( and see below).
Similar to TZM-bl cells , two types of viral marker redistribution events were observed with CEM-derived cells. First, the membrane marker signal (red) quickly dropped to the background level while the signal from the GFP-tagged viral content (green) remained relatively constant (Figure 3A). The lack of viral content release concomitant with a drop of the lipid marker is suggestive of virus hemifusion at the cell surface. Particles undergoing hemifusion usually exhibited limited movement before and immediately after the lipid mixing step (Figure 3B). In fact, the limited displacement of these viral particles from their initial position was often caused by cell motility associated with a steep increase in temperature at the beginning of the experiment. The second type of events was characterized by disappearance of the viral content marker while the fluorescence of the membrane dye remained virtually unchanged indicating endosomal fusion (Figure 3C). In this case, we ordinarily observed more extensive virus movement before the content release events were detected (Figure 3D).
Out of the total 1238 co-labeled viral particles, 29 (2.3%) appeared to hemifuse with the plasma membrane, while only 7 (0.6%) underwent full fusion within endosomes (Figure 3E). Thus, the efficiency of JRFL fusion with the CEM-derived cell line was relatively low. As with TZM-bl cells, JRFL fusion was primarily initiated at the cell surface, resulting in lipid mixing but not the viral content release. Also, as previously observed , the kinetics of lipid mixing at the plasma membrane was considerably faster than the viral content release from endosomes (Figure 3E), consistent with the delayed endocytic entry of this virus. Importantly, the faster rate of hemifusion at the surface of TZM-bl and CEM.NKR-CCR5.Luc cells compared to that of the content release shows that the lack of HIV-1 fusion with the plasma membrane was not due to a quick particle internalization, as suggested in . Clearly, HIV-1 Env often initiates fusion with the plasma membrane earlier than the virus gets internalized but fails to create a functional fusion pore. In summary, both the BlaM and single virus imaging assays (Figures 2 and 3) imply that HIV-1 enters into a number of cell lines and into primary CD4+ T cells through endocytosis.
Synchronizing HIV-1 entry through trapping the virus-CD4-coreceptor complexes at the cell surface does not favor fusion with the plasma membrane
We sought to optimize and accelerate the HIV-1 fusion reaction in an attempt to redirect it from an endocytic pathway to the plasma membrane. This was achieved by pre-incubating the viruses with target cells at sub-threshold temperature for fusion (18-24°C), which resulted in creation of a temperature-arrested stage (TAS) [23, 30]. Under these conditions, a large fraction of Env engages a requisite number of CD4 and coreceptors, as evidenced by resistance of fusion to high concentrations of CD4  and coreceptor binding inhibitors added at TAS [23, 30]. Our previous studies using a cell-cell model demonstrated that fusion from TAS induced by raising the temperature was markedly accelerated compared to control cells pre-incubated at 4°C [30, 36]. We, therefore, reasoned that HIV-cell fusion from this intermediate stage would also be accelerated, thus favoring direct fusion with the plasma membrane prior to the virus uptake.
Pseudoviruses bearing JRFL or HXB2 Env were pre-bound to TZM-bl cells at 4°C, and TAS was created by incubation at a temperature just below the threshold for fusion for 2.5 h. The empirically determined optimal temperatures for creating TAS were ~21°C for JRFL and ~24°C for HXB2. Under these conditions, only 10-20% of fusion-competent JRFL or HXB2 particles acquired resistance to C52L (Figure 4A and 4B, red circles), apparently due to the limited virus uptake/fusion during the extended pre-incubation at sub-threshold temperature. At the same time, 50-75% of virions became resistant to CD4 and coreceptor binding inhibitors added immediately before raising the temperature from TAS (pink vs. yellow symbols, respectively), confirming that a large portion of viruses had engaged both molecules. Control samples kept for 2.5 h at 4°C exhibited minimal or no resistance to HIV-1 entry inhibitors, consistent with the lack of Env-CD4-coreceptor interactions or virus uptake (black, blue and green symbols). We next tested if the creation of TAS accelerated HIV-1 entry/fusion, as was the case for the cell-cell fusion process [30, 36]. When fusion was initiated by shifting to 37°C, viruses captured at TAS acquired resistance to C52L faster than control viruses pre-incubated at 4°C (Figure 4A and 4B). This effect was more pronounced for HXB2 compared to JRFL pseudoviruses. However, as we have previously shown , escape from C52L alone does not unambiguously prove that fusion occurs at the cell surface. If fusion takes place in endosomes, the virus resistance to C52L would be acquired at an earlier time through productive endocytosis (Figure 1).
In order to assess the HIV-1 entry pathway after creating TAS, we performed comparative measurements of the escape kinetics from C52L and TB. These measurements were carried out using HXB2 particles, since HXB2 exhibited a more pronounced acceleration of entry from TAS (Figure 4A and 4B). As in Figure 4B, after creating TAS, resistance to C52L was acquired faster than in control samples (Figure 4C, red vs. black circles). However, the rates of virus escape from TB were markedly delayed relative to escape from C52L, both for TAS-arrested and control samples (triangles vs. circles). We thus concluded that, in spite of engaging CD4 and coreceptors at the cell surface, the virus still failed to fuse with the plasma membrane. Instead, the creation of TAS appeared to accelerate productive HIV-1 endocytosis, whereas fusion with endosomes (escape from TB) occurred at the same rate as in control experiments (red vs. black triangles). In other words, the rate of endosomal fusion was virtually independent of the rate of virus uptake.
In parallel experiments, we imaged single HXB2 pseudovirus fusion with TZM-bl cells after creating TAS and in control samples pre-incubated in the cold for 2.5 hours. However, very few fusion events (content release from endosomes) were detected for cold pre-incubated cells following the subsequent incubation at 37°C for 35 minutes, whereas fusion was consistently observed after creating TAS (Figure 4D, black vs. red circles). The shorter incubation time at 37°C and the necessity to keep cells on ice prior to imaging (see Materials and Methods) could contribute to the lower tolerance of single virus fusion to pre-incubation in the cold. To aid the assessment of the effect of TAS on the kinetics of HIV-1 fusion, we compared cells pre-incubated at 24°C to those imaged immediately after the virus binding step (Figure 4D, blue circles). This comparison revealed that, in agreement with the BlaM results, the rate of single virus fusion after TAS (proportional to the slope of plots in Figure 4D) was virtually identical to that without pre-incubation (Figure 4D, red vs. blue circles). However, in control samples fusion commenced after about a 10 min lag, whereas fusion after TAS proceeded without a delay. The nearly identical kinetics of fusion measured by the BlaM assay with or without creating TAS (Figure 4C, triangles) indicates that the BlaM activity might occur after an additional rate-limiting step, such as a slow dilation of fusion pores between HIV-1 and endosomes. Importantly, the creation of TAS neither eliminated the kinetic differential between C52L and TB in BlaM experiments nor allowed single virus fusion at the cell surface in imaging experiments.
Collectively, our data imply that synchronization of HIV-1 fusion through formation of Env-CD4-coreceptor complexes at the cell surface does not favor direct fusion at that site. These conditions accelerate productive endocytosis (escape from C52L), while the rate of fusion with endosomes (escape from TB) remains unaltered. The observation that after creation of TAS HIV-1 appears to spend more time within intracellular compartments prior to undergoing fusion highlights the role of endosome trafficking/maturation in facilitating the virus entry.
Blocking HIV-1 uptake by a dynamin inhibitor allows lipid mixing but not full fusion with the plasma membrane
Another strategy to redirect HIV-1 fusion to the plasma membrane was based on preventing the virus endocytosis at physiological temperature. We used the small-molecule dynamin inhibitor, dynasore , which suppresses HIV-1 endocytosis and fusion . Virions trapped at the cell surface in the presence of this inhibitor quickly lost their fusion competence, as evidenced by the lack of recovery of the BlaM signal following the removal of this inhibitor (supplemental material to ). However, whether or not HIV-1 underwent hemifusion (lipid mixing) under these conditions remained unclear, owing to the strong quenching of the viral DiD fluorescence by dynasore (, data not shown).
We further examined the nature of the dynasore-imposed block of HIV-1 fusion. In agreement with the previous results , dynasore strongly quenched the DiD signal (Figure 5A), as well as the fluorescence of its green analogue, DiO, and of the chemically distinct membrane probe, R18 (Additional File 1: Figure S1A-D), showing that the quenching effect was not specific for the chemical structure or spectral characteristics of DiD. In contrast to lipophilic dyes, dynasore did not alter the signal from the viral content markers, Gag-mKO or Gag-GFP (Additional File 1: Figure S1A-B). However, other dynamin inhibitors, dynole 34-2 and MiTMAB, did not affect the DiD fluorescence (Additional File 1: Figure S1E-G). Analysis of the mean DiD fluorescence of cell-bound viruses confirmed the loss of the red signal, while the mKO fluorescence was not significantly affected by dynasore (Figure 5B). Importantly, we did not detect any viral content release events at the cell surface with or without dynasore (Figure 5).
In order to determine whether, in addition to the direct DiD quenching by dynasore, a fraction of this signal could be lost through HXB2-cell hemifusion, imaging experiments were performed in the presence of both dynasore and a fully inhibitory concentration of C52L. As expected, the overall fluorescence decayed when fusion was blocked by C52L (Figure 5B), but the diminution of the lipid dye fluorescence was less pronounced than in the presence of dynasore alone. When C52L was added during imaging, the DiD/mKO ratio dropped by ~60% within the 40 min-incubation period, as compared to ~85% in the absence of the peptide inhibitor. The sensitivity of DiD quenching to C52L indicates that a sizeable fraction of events resulting in disappearance of DiD puncta (perhaps as much as 25%, Figure 5B) are due to the HIV-1 Env-mediated release of the lipid marker into the plasma membrane. This is in contrast to rare lipid mixing events observed in the absence of dynamin inhibitor .
To verify that HIV-1 can exchange lipids with the plasma membrane in the presence of dynasore, we tracked single HXB2 and JRFL particles. This analysis revealed two distinct types of DiD disappearance events - fast, exhibiting a nearly instantaneous drop of fluorescence (Figure 5C, D), and slow, lasting 10 min or longer (Figure 5E, F). When experiments were performed in the presence of both dynasore and C52L, fast events were virtually abrogated while the slow events remained. Figure 5G shows the inhibition of the fast DiD decay events in the presence of dynasore and C52L and concomitant disappearance of already infrequent content release from endosomes. In contrast, slow DiD decay was not noticeably affected by the presence of C52L (data not shown). These findings are consistent with the notion that the slow loss of DiD fluorescence is caused by dynasore, whereas the fast DiD decay reflects transfer of viral lipids into the plasma membrane mediated by Env. By definition, lipid mixing in the absence of content release corresponds to a hemifusion phenotype.
We found that 17% of single viruses quickly released DiD into the plasma membrane (Figure 5G), a number that was comparable to the estimated fraction of hemifusion events in the presence of C52L based on the global image analysis (Figure 5B). In summary, through trapping HIV-1 at the cell surface, we increased the occurrence of Env-mediated lipid mixing. However, in spite of the exaggerated hemifusion phenotype in the presence of dynasore, viruses failed to undergo full fusion with the plasma membrane.
Dynasore incorporates into lipid membranes without significantly affecting their propensity to fuse
The DiD-quenching activity of dynasore prompted us to investigate its effect on the stability of lipid bilayers and their propensity to undergo hemifusion/fusion. We first tested whether dynasore could directly inactivate the virus. Pre-treatment of viruses with dynasore did not significantly decrease virus-cell binding  or the fusion activity (Figure 6A) compared to control viruses. We also did not detect adverse effects of dynasore on infectivity of immobilized viruses (data not shown). Because dynasore did not exhibit a direct virucidal effect on HIV-1, we concluded that the previously observed virus inactivation by this compound  was dependent on HIV-cell contact.
We then asked whether, in addition to quenching the fluorescence of lipid dyes, dynasore can also affect the propensity of virus and/or cell membranes to undergo hemifusion/fusion. Toward this goal we measured the temperature of the lamellar-inverted hexagonal (HII) phase transition (TH) in pure lipid bilayers in the presence of dynasore and another dynamin inhibitor, MiTMAB. Compounds that lower the TH promote negative membrane curvature required for the formation of a stalk intermediate between two fusing bilayers, whereas compounds that raise the transition temperature are inhibitory for fusion [37–40]. To determine how modulators of dynamin activity affect membrane curvature, we studied the ability to shift the T-H of a model lipid, dipalmitoloeoyl phosphatidylethanolamine (DiPoPE). This lipid has a TH at about 45°C and is convenient for these types of studies [41–43]. When dynasore was mixed with DiPOPE, it lowered the TH of this lipid in a dose-dependent manner (Figure 6B). However, this effect was weak compared to known promoters of negative curvature, such as diacylglycerol . In contrast, MiTMAB, which inhibits dynamin activity by preventing its binding to phospholipids , strongly increased the TH (Figure 6B), in agreement with the previous study . Thus, MiTMAB promotes strong positive curvature and is thereby expected to inhibit bilayer hemifusion, whereas dynasore confers weak negative curvature that is unlikely to be of consequence for HIV-1 fusion.
To test whether the dynasore's modest effect on lipid bilayers can modulate HIV-1 Env-mediated fusion, we analyzed the kinetics of virus-cell hemifusion in the presence of this compound. The waiting times from initiating the virus fusion by raising the temperature to each fast lipid mixing event were measured and plotted as the number lipid mixing events over time. We found that lipid mixing between HIV-1 and the plasma membrane occurred at the same rate, irrespective of the presence of dynasore (Figure 6C). Consistent with our previous study , HXB2 pseudoviruses rarely exchanged lipids with the plasma membrane. The number of observed hemifusion events in the absence of dynasore appears truncated, likely due to the virus clearance from the cell surface through endocytosis. The invariant kinetics of hemifusion suggests that dynasore itself does not facilitate membrane merger, in agreement with its weak effect on the lipid curvature (Figure 6B). We therefore concluded that the increased number of hemifusion events in the presence of dynasore was caused by trapping of viruses at the cell surface and thus extending the window of opportunity for lipid mixing. Notably, the previously observed loss of HIV-1 fusion activity following a pre-incubation of cell-bound pseudoviruses with dynasore  occurred over the same time course (20 min at 37°C) as the hemifusion events (Figure 6C). These data suggest that dead-end hemifusion is responsible for inactivation of cell-bound HIV-1 in the presence of dynasore.
Dynasore more potently blocks HIV-1 endocytosis than subsequent fusion with endosomes
If an inhibitor can target more than one step of virus entry, time of addition experiments would reveal the latest step of this process affected by inhibitor. We have previously reported that HIV-1 escapes from dynasore and the TB with nearly identical kinetics, while acquiring resistance to a peptide inhibitor at an earlier time . This finding thus implies that dynasore not only blocks HIV-1 endocytosis, but also inhibits the virus-endosome fusion step. However, a fluorescence quenching activity of dynasore raised concerns regarding possible off-target effects of this compound. We therefore re-tested the effect of dynasore from different commercial sources on HIV-1 fusion. At 80 μM, all tested preparations efficiently blocked transferrin uptake in TZM-bl cells without exhibiting significant cytotoxicity (Additional File 2: Figure S2A-G and Additional File 3: Figure S3A). At this concentration, dynasore preparations effectively inhibited fusion between HXB2 pseudoviruses and TZM-bl cells (Figure 7A). By contrast, another dynamin inhibitor dynole 34-2, when used at 80 μM, only partially inhibited transferrin uptake (Additional File 2: Figure S2H, I) and exhibited only a minor effect on HIV-1 fusion (Figure 7A) or endocytosis (Additional File 4: Figure S4). Since higher concentrations of dynole 34-2 were toxic to TZM-bl cells (Additional File 3: Figure S3B) we did not further investigate this compound. The effect of dynasore on HXB2 fusion with CEMss cells was also evaluated.
We found that dynasore inhibited HIV-1 fusion with CEMss cells as effectively as with TZM-bl cells (Figure 7A, green bars) without significantly affecting the cell viability (data not shown). Furthermore, 80 μM of dynasore abrogated HXB2 fusion with primary CD4+ T cells (Figure 7B, filled bars). The viability of these cells was not compromise by this concentration of dynamin inhibitor (Figure 7B, dark cyan bars). The potent block of HIV-1 fusion with primary T cells by dynasore further supports the endocytic entry route of this virus.
A considerable lag between HIV-1 escape from C52L and the TB in TZM-bl cells (Figure 2) indicates that virus might rely on endosomal trafficking and maturation in order to undergo fusion. To test whether dynasore could exert its inhibitory effect on HIV-1 fusion by interfering with cellular trafficking, we imaged single virus movement within target cells and applied a fully inhibitory dose of dynasore at an arbitrary time point. The lack of noticeable effect on virus trafficking (Additional File 5: movie 1) argued against the possibility that dynasore could interfere with molecular motors or cytoskeletal components involved in virus trafficking. Using cells transfected with GFP-Rab5, we also found that this compound did not affect a general movement pattern of endosomes (Additional File 6: movie S2). To conclude, we did not detect any obvious off-target effects of dynasore in TZM-bl cells.
To evaluate the last step of HIV-1 entry targeted by dynasore, we compared the rates of virus escape from C52L (receptor-mediated endocytosis), TB (fusion with endosomes) and from dynasore added at varied times of virus-cell incubation at 37°C. Out of five dynasore preparations tested, only the Santa Cruz compound appeared to inhibit HIV-endosome fusion step (coinciding with the TB-sensitive step) at 80 μM, similar to dynasore previously obtained from T. Kirchhausen (Figure 7C and ). For other tested dynasore preparations, the rate of HIV-1 escape from this inhibitor tended to be closer to that for C52L (Figure 7D, E and data not shown) than to the TB, consistent with inhibition of receptor-mediated virus endocytosis. However, when the concentration of different dynasore preparations was increased to 160 μM, delayed escape from this compound was reproducibly observed (Figure 7D, E), suggesting that the higher dose of dynasore targeted the HIV-endosome fusion step.
Taken together, our results showed that dynasore reproducibly blocked HIV-1 endocytosis and fusion, but that the rate of virus escape from this compound varied somewhat depending on the dynasore preparation. The remarkable switch between inhibiting receptor-mediated endocytosis to blocking virus-endosome fusion that occurred in a narrow range of dynasore concentrations could be indicative of a more stringent requirement for dynamin to pinch off endocytic vesicles compared to its apparent role in aiding the HIV-1 fusion with endosomes. Interestingly, dynasore has been shown to block transferrin uptake in HeLa cells at lower doses compared to those required to inhibit HIV-1 endocytosis ( and Fig. 8), perhaps suggesting the involvement of factors other than dynamin in virus internalization.
A large number of viruses enter host cells through intracellular compartments where low pH and/or cellular proteases activate the viral fusion proteins, permitting the release of the virus' genome from intracellular compartments [23, 47, 48]. Studies of virus entry helped identify new routes of endosomal trafficking. However, the entry pathways of enveloped viruses that do not rely on low pH to activate their fusion proteins are less well understood. These viruses can enter both via direct fusion with the plasma membrane and endocytosis. Indeed, several viruses undergoing receptor-mediated fusion at neutral pH appear to rely on endocytosis for productive entry [49–51]. Studies aimed at determining the HIV-1 entry site yielded contradicting evidence for and against the involvement of endocytosis in productive entry of this virus [5–7, 12, 20, 21]. The fact that HIV-1 does not rely on low pH to infect most target cells [8, 18, 19] has confounded the identification of its entry pathways. Non-invasive functional approaches developed by our group  showed that, surprisingly, HIV-1 fusion initiated at the cell surface was blocked at a post lipid mixing step, whereas internalized viruses underwent complete fusion with endosomes. However, the molecular basis for the strong preference for entry from intracellular compartments was not delineated and some evidence supporting the HIV-1 fusion with the plasma membrane, including the virus' ability to fuse adjacent cells , remained controversial.
In this study, we provided further evidence that HIV-1 enters distinct permissive cell lines and primary CD4+ T cells through endocytosis and fusion with endosomes. This conclusion was supported by a lag between HIV-1 escape from C52L and from the TB, which was cell type-dependent, but independent of coreceptor tropism (Figure 2A). This lag was also not affected by attempts to synchronize fusion by creating TAS (Figure 4C). The cell type-dependent difference of the kinetics of virus escape from C52L and low temperature is consistent with the essential role of endosome trafficking and maturation for HIV-1 entry. The HIV's reliance on endocytic pathways is further supported by single virus imaging in lymphoid cells, in which we observed hemifusion with the plasma membrane and complete fusion with endosomal compartments. More importantly, attempts to redirect HIV-1 fusion to the plasma membrane, either by synchronizing the multistep fusion reaction or by trapping the virus on the cell surface using dynasore, were unsuccessful. In spite of the ability to quench the fluorescence of lipophilic dyes, dynasore does not strongly affect the properties of lipid bilayers that are essential for fusion or modulate the kinetics of hemifusion at the cell surface. It is thus unlikely that the lack of complete fusion between HIV-1 and the plasma membrane is due to an inadvertent effect of dynasore.
On the other hand, a short lag between HIV-1 escape from C52L compared to escape from the TB observed in Jurkat and in primary T cells is consistent both with endocytic entry and with fusion at the cell surface. However, based on the single virus imaging data (Figure 3), we propose that HIV-1 fuses with early endosomal compartments of lymphoid cells. The potent inhibition of HIV-1 fusion with CEMss cells by dynasore (Figure 7A) supports this notion. Future studies of single virus fusion in cells exhibiting minimal kinetic differential between the virus escape from C52L and TB in BlaM experiments should reveal whether these cells support HIV-1 fusion with the plasma membrane.
A recent study has demonstrated that the centrifugal force applied to cells during spinoculation with viruses enhances HIV-1 infection by promoting actin dynamics . Although virus spinoculation was used in our studies, actin remodeling should only promote direct fusion at the cell surface . It thus appears that HIV-1 fusion with the plasma membrane is disfavored compared to fusion with endosomal compartments. We have previously speculated that a handful of Env glycoproteins incorporated into a virion  may not be able to promote dilation of a fusion pore formed at the cell surface, whereas the viral content release from intracellular compartments is aided by yet unknown endosomal factor(s) . Based on the late escape of HIV-1 from inhibition by dynasore, which coincided with the escape from the temperature block ( and Figure 7), it appears that dynamin can be involved in the virus-endosome fusion step. In other words, this GTPase can control HIV-1 entry at two check points - receptor-mediated uptake and fusion with endosomes. It remains to be determined whether dynasore can also inhibit HIV-endosome fusion in T cells.
The requirement for a somewhat higher concentration of dynasore to block HIV-endosome fusion compared to a dose that inhibits productive endocytosis (Figure 7D and 7E) indicates that the fusion step may be less reliant on dynamin activity than virus uptake. The possibility of the dynamin involvement in HIV-endosome fusion is not surprising, considering that this protein plays a role in a number of cellular processes besides vesicle budding from the plasma membrane (reviewed in ). In particular, dynamin has been shown to regulate receptor trafficking from late endosomes to lysosomes , as well as from late endosomes to the Golgi and ER [57–59]. Furthermore, dynasore has been reported to block SV40 infection by inhibiting endosomal trafficking downstream of a nocodazole-sensitive step . It is thus possible that dynamin directly or indirectly promotes dilation of a fusion pore connecting the HIV-1 envelope and an endosomal membrane.
This study expanded and reinforced our previous finding that HIV-1 enters susceptible cells by fusing with endosomes. First, we demonstrated the existence of a lag between HIV-1 uptake and fusion in cell lines of different origin and in primary CD4+ T cells. Second, consistent with HIV's reliance on endosomal trafficking, the progression of fusion beyond the temperature-sensitive steps occurred at different rates in epithelial, glial and lymphoid cells. Third, the time of addition experiments using dynasore implied that this compound blocked fusion of internalized viral particles. Fourth, imaging single virus fusion with lymphoid cells identified endosomes as HIV-1 entry sites. Finally, in an attempt to redirect HIV-1 fusion to the plasma membrane, we blocked the virus uptake. HIV-1 particles trapped on the cell surface released a lipid marker but failed to undergo complete fusion. Collectively, our data strongly support the notion that HIV-1 infects cells by entering and fusing with endosomes and that dynamin plays a role in virus uptake and in the subsequent virus-endosome fusion.
Cells and Reagents
HeLa-derived indicator TZM-bl cells expressing CD4, CXCR4 and CCR5 (donated by Drs. J.C. Kappes and X. Wu ), human T4-lymphoblastoid CEMss cells (donated by Dr. P. Nara ), CEM-NKR-CCR5-Luc cells (donated by Drs. J. Moore and C. Spenlehauer ), PM-1 cells (donated by Drs. P. Lusso and R. Gallo ) and human astroglioma U87-MG-derived U87.CD4.CCR5 cells (donated by Dr. H. Deng and Dr. D.R. Littman ) were obtained from the NIH AIDS Research and Reference Reagent Program. Jurkat and human embryonic kidney 293T/17 cells were obtained from the ATCC (Manassas, VA). TZM-bl were grown in Dulbecco's Modified Eagle Medium (DMEM, Cellgro, Manassas, VA), whereas CEMss, CEM-NKR-CCR5-Luc, Jurkat, and PM-1 cells were grown in RPMI-1640 (Cellgro) supplemented with 10% Fetal Bovine Serum (FBS, HyClone Laboratories, Logan, UT) and 100 U penicillin-streptomycin (Gemini Bio-Products, West Sacramento, CA). U87.CD4.CCR5 were maintained in DMEM supplemented with 15% FBS, 100U penicillin-streptomycin, 0.5 mg/ml G418 sulfate (Cellgro), and 1 μg/ml puromycin (Sigma, St. Louis, MO). HEK 293T/17 cells were maintained in DMEM supplemented with 10% FBS, 100 U penicillin/streptomycin and 0.5 mg/ml G418 sulfate. Primary peripheral blood mononuclear cells (PBMCs) were purified from the peripheral blood of healthy donor (approval from Emory IRB000045690 "Phlebotomy of Healthy Adults for Research in Infectious Diseases and Immunology") by Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ) density gradient centrifugation. CD4+ T lymphocytes were isolated from PBMCs by depletion of non-CD4+ cells (negative selection) using MACS CD4+ T Cell Isolation kit II (Miltenyi Biotec, Auburn, CA) and MACS LD columns (Miltenyi Biotec, Auburn, CA). Purified CD4+ T cells were cultured in RPMI medium supplemented with 10% FBS, 10 ng/ml of Interleukin-2 (NIH AIDS Reagent Program), 2.5 μg/ml of phytohemagglutinin P (Sigma, St. Louis, MO) to activate the cells. Three days after cultivation, the purified cells were used for the assay.
The pCAGGS plasmids encoding full length or tail-truncated JRFL or HXB2 envelope glycoproteins (Env) were provided by Dr. J. Binley (Torrey Pines Institute, CA) . The HIV-1 based packaging vector pR8ΔEnv lacking the env gene was from Dr. D. Trono (University of Geneva, Switzerland). HIV-1 BaL.01 Env expression vector (donated by Dr. J. Mascola ) and the pMM310 vector expressing BlaM-Vpr (donated by Dr. M. Miller  were obtained from the NIH AIDS Research and Reference Reagent Program. Vectors expressing MLV Gag-pol, Gag-GFP, and the MLV LTR lacZ  were provided by Dr. W. Mothes (Yale University).
The C52L recombinant peptide  was a gift from Dr. Min Lu (Cornell University). The BMS-806 compound [69, 70] was synthesized by ChemPacific Corp. (Baltimore, MD), AMD3100  and pronase were purchased from Sigma, and AD101  was a gift from Dr. J. Strizki (Schering Plough, Kenilworth, NJ). Dynasore was purchased from Ascent Scientific LLC (Princeton, NJ), Calbiochem (Gibbstown, NJ), Santa Cruz Biothechnology (Santa Cruz, CA), Sigma (St. Louis, MO) and Tocris Bioscience (Ellisville, Missouri). Dynole 34-2 and dynole 31-2 (negaive control for dynole 34-2) were purchased from Ascent Scientific. DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt), DiO (3,3'-dilinoleyloxacarbocyanine perchlorate) and R18 (octadecyl rhodamine B) were purchased from Invitrogen (Carlsbad, CA). Myristyltrimethylammonium Bromide (MiTMAB) was obtained from Calbiochem. Hanks' Balanced Salt Solution with calcium and magnesium (HBSS++) and poly-L-lysine were from Cellgro and Sigma, respectively.
pMLV-Gag-mKO plasmid was constructed by modifying the pMLV-Gag-YFP plasmid . The mKO sequence was amplified by PCR using KOD Xtreme DNA polymerase (Novagen, Gibbstown, NJ) and the forward and the reverse primers, 5'-TTGCGGATCCGGCGGCGGTGGAGCTAGCGTGAGTGTGATTAAACCAGAGATG -3' and 5'-TTCCGCCGGCTTAGATATCGGAATGAGCTACTGCATCTTCTAC-3', containing BamHI and NaeI restriction enzyme cleavage sites, respectively. The amplified fragment was cloned into pCR4 Blunt-TOPO vector (Invitrogen) and its sequence was verified. The YFP sequence in the pMLV-Gag-YFP was replaced with the mKO sequence from pCR4 Blunt-TOPO using BamHI and NaeI restriction sites.
Virus production and characterization
To produce pseudoviruses containing the β-lactamase-Vpr (BlaM-Vpr) a 10 cm dish of 293T/17 cells were transfected with 2 μg pR8ΔEnv, 2 μg pMM310 vector expressing BlaM-Vpr, 1 μg pcRev , and 3 μg pCAGGS encoding JRFL or HXB2 or the BaL.01 expression vector, using PolyFect Transfection reagent (Qiagen, Valencia, CA). Fluorescently labeled pseudoviruses were produced by the PolyFect transfection of 293T/17 cells with 2 μg MLV-Gag-pol, 1 μg MLV-Gag-GFP or MLV-Gag-mKO, and 3 μg of the cytoplasmic tail-truncated HXB2 Env or JRFL Env provided by Dr. James Binley . Twenty four hours post-transfection, cells were labeled with either 10 μM DiD, DiO or R18 for 4 h in the CO2 incubator at 37°C, as described in , washed and incubated for an additional 24 h in fresh growth media. Forty eight hours post-transfection virus-containing media was collected, passed through 0.45 μM filters, aliquoted and stored at -80°C. The infectious titer was determined by a β-Gal assay in TZM-bl cells .
Virus-cell fusion assay
Measurements of HIV-1 fusion with target cells were carried out as described previously . Briefly, viruses bearing the BlaM-Vpr chimera (MOI = 1) were bound to TZM-bl cells by centrifugation at 2095 × g, 4°C for 30 min. Unbound virus was washed off and fusion was initiated by shifting to 37°C and stopped after indicated times either by adding the respective inhibitors or by placing cells on ice (TB). Cells were then loaded with fluorescent CCF4-AM substrate (Invitrogen) and incubated overnight at 12°C. To measure HIV-1 fusion with suspension PM-1, CEMss or Jurkat cells or primary CD4+ T cells were harvested by centrifugation (453 × g, 5 min at 4°C) and resuspended in HBSS++ at 1·106 cells/ml. Aliquots of 1·105 cells/well were added to a poly-L-lysine-coated 96-well strip plate (Corning Costar) and cells were allowed to attach for 30 min at room temperature. Unbound cells were removed by washing with HBSS++, and the plates were blocked with 100 μl/well of HBSS++/10% FBS for 15 min at room temperature. Viruses bearing the BlaM-Vpr were bound and the fusion was initiated as described above. Intracellular β-lactamase activity (ratio of blue to green fluorescence) was measured using the Synergy HT fluorescence microplate reader (Bio-Tek, Germany).
To create the temperature-arrested stage (TAS) pseudoviruses (MOI = 0.8) were bound to TZM-bl cells by spinoculation at 2095 × g for 30 min at 4°C. Unbound virus was washed off, and the cells were incubated either at 22-24°C (HXB2 pseudoviruses), at 18-21°C (JRFL pseudoviruses) or at 4°C for 2.5 h. A high concentration (10 μM) of inhibitors of CD4 binding (BMS-806), and CXCR4 or CCR5 binding (AMD3100 and AD101, respectively) or of gp41 6-helix-bundle formation (C52L, 1 μM) were added either immediately prior to raising the temperature to 37°C (0 min) or after the indicated times. At the end of the 37°C incubation, cells were chilled and then loaded with fluorescent CCF2-AM substrate (Invitrogen) and incubated overnight at 12°C.
Cell viability assay
Cytotoxic effects of dynamin inhibitors were evaluated by the MTS assay, using CellTiter 96 Aqueous reagent (Promega) according to the manufacturer's specifications. Briefly, 1·105 cells per well in a 96-well plate were treated with 50 μl DMEM containing specified compounds for 90 min at 37°C, after which time, DMEM was replaced with 50 μl DMEM/10% FBS containing 10 μl of CellTiter 96 Aqueous reagent. The cells were further incubated for additional 2 h at 37°C. The resulting absorbance from wells was recorded at 490 nm, using a plate reader.
Diferential scanning calorimetry
Dynasore (Santa Cruz Biotechnology) was dissolved in a mixture of chloroform:methanol 2:1 to make a 1 mg/ml solution. A preparation of a dynasore monohydrate supplied by Sigma was found to have poorer solubility in non-polar solvents and showed somewhat poorer mixing with DiPoPE. Only the results from the Santa Cruz preparation are reported here. The dynamin inhibitor, MiTMAB, was dissolved in methanol so as to make a 1 mg/ml solution. Aliquots of these solutions were added to a set of tubes each containing 5 mg DiPoPE in chloroform:methanol 2:1, to end up with mole fractions of drug ranging from 0 to ~0.05. The solvent was evaporated under a stream of nitrogen gas so as to make thin films on the walls of the glass tubes. The tubes were further dried for three hours in a vacuum desiccator and kept under argon gas at -20°C until use. For calorimetry, the films were suspended in 0.8 ml PIPES buffer (20 mM PIPES, 1 mM EDTA, 140 mM NaCl, pH 7.4) with vigorous vortexing, degassed and added to the calorimeter cell at room temperature, with pure buffer in the reference cell. Temperature scans were made from 15 to 55°C at a 1°/min scan rate. The transition temperature for the liquid crystalline to the inverted hexagonal phase of DiPoPE is ~45°C. The transition temperature for each mixture was determined from a heating scan using a curve fitting program DA-2 supplied by Microcal, Inc. (Northampton, MA).
Single virus imaging and image analysis
Fluorescence changes caused by dynasore and other compounds were monitored by adhering double-labeled viruses (~ 0.5·105 infectious units) for 30 min at 4°C to 8-well chamber slides (Lab-Tek) pre-coated with 0.1 mg/ml poly-L-lysine. Images were acquired every 10 sec for 10 min at room temperature, using the Personal DeltaVision imaging system (Applied Precision LLC., Issaquah, WA). Two consecutive images were acquired at each time point, by alternating the standard FITC, TRITC or CY5 excitation/emission filters, depending on the fluorescent probes used. Green and orange/red signals were separated by a quad (DAPI/FITC/TRITC/Cy5) dichroic beam-splitter and sequentially acquired using an EM-CCD camera (Photometrics).
For imaging HIV pseudovirus fusion, cells were grown overnight on 35mm Lab-Tek glass bottom dishes to approx. 90% confluency. Before imaging, cells were washed once with HBSS++, and pseudoviruses (MOI ~ 0.2) were spinoculated onto cells at 2095 × g for 30 min at 4°C. Free virus was removed by washing with cold HBSS++, cells were covered with 100 μl of cold HBSS++ and transferred into an environmental enclosure maintained at 37°C. Once a suitable image field was found (within 1 min after transferring into the enclosure), 1 ml of pre-warmed HBSS++ was added to the plate to initiate virus uptake and fusion, and image acquisition started. Images were acquired using the Personal DeltaVision imaging system using a UPlanFluo 40x/1.3NA oil-immersion objective (Olympus). Two consecutive images with 3 Z-sections 2.5 μm apart were acquired every 10 sec for 40 min by alternating the standard excitation/emission filters as listed above.
For confocal imaging of virus fusion, CEM.NKR-CCR5.Luc cells were attached to No. 0 glass coverslips coated with poly-L-lysine by a brief (20 min) centrifugation at 12°C, 600 × g, as described in . Loosely bound cells were removed by washing, and coverslips were further centrifuged with the pseudovirus inoculum for 40 min at 12°C, 1000 × g. Cells were washed again and kept on ice for no longer than 3 h prior to imaging. Pieces of coverslip were then transferred into a custom-made glass-bottom imaging chamber, and virus fusion was initiated by raising the temperature locally to 37°C, using a custom-built temperature-jump setup . Images were acquired with the C-Apo 40×/1.2NA water immersion objective, using the Zeiss LSM510Meta confocal microscope. Fluorescence signals from Gag-GFP and DiD labeled viruses were separated using a standard filter set. Three Z-sections separated by 3.0 μm were acquired at each time point with the pinhole set to 340 μm.
The HIV-1 pseudovirus fusion with TZM-bl cells was imaged as described previously , except that viruses were bound to cells by spinoculation at 4°C and additionally incubated for 2.5 h at 24°C to create TAS (or at 4°C in control experiments). Cells were kept on ice for up to 3 h and used for visualizing HIV-1 entry and fusion by confocal microscopy, as detailed above.
HIV-1 gp41-derived inhibitory peptide
temperature-arrested stage of HIV-1 fusion
bilayer to hexagonal (HII) phase transition temperature.
Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999, 17: 657-700. 10.1146/annurev.immunol.17.1.657.
Doms RW: Chemokine receptors and HIV entry. Aids. 2001, 15 (Suppl 1): S34-35.
Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R: The HIV Env-mediated fusion reaction. Biochim Biophys Acta. 2003, 1614: 36-50. 10.1016/S0005-2736(03)00161-5.
Melikyan GB: Membrane fusion mediated by human immunodeficiency virus envelope glycoprotein. Curr Top Membr. 2011, 68: 81-106.
Bedinger P, Moriarty A, von Borstel RC, Donovan NJ, Steimer KS, Littman DR: Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature. 1988, 334: 162-165. 10.1038/334162a0.
Maddon PJ, McDougal JS, Clapham PR, Dalgleish AG, Jamal S, Weiss RA, Axel R: HIV infection does not require endocytosis of its receptor, CD4. Cell. 1988, 54: 865-874. 10.1016/S0092-8674(88)91241-X.
Stein BS, Gowda SD, Lifson JD, Penhallow RC, Bensch KG, Engleman EG: pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell. 1987, 49: 659-668. 10.1016/0092-8674(87)90542-3.
McClure MO, Marsh M, Weiss RA: Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. Embo J. 1988, 7: 513-518.
Clavel F, Charneau P: Fusion from without directed by human immunodeficiency virus particles. J Virol. 1994, 68: 1179-1185.
Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol. 1998, 72: 7992-8001.
Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR: Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem. 2002, 277: 17291-17299. 10.1074/jbc.M108232200.
Pelchen-Matthews A, Clapham P, Marsh M: Role of CD4 endocytosis in human immunodeficiency virus infection. J Virol. 1995, 69: 8164-8168.
Aiken C: Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol. 1997, 71: 5871-5877.
Agosto LM, Yu JJ, Liszewski MK, Baytop C, Korokhov N, Humeau LM, O'Doherty U: The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T cells than the vesicular stomatitis virus glycoprotein G envelope. J Virol. 2009, 83: 8153-8162. 10.1128/JVI.00220-09.
Pace MJ, Agosto L, O'Doherty U: R5 HIV Env and VSV-G Cooperate to Mediate Fusion to Naive CD4+T Cells. J Virol. 2010
Yu D, Wang W, Yoder A, Spear M, Wu Y: The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog. 2009, 5: e1000633-10.1371/journal.ppat.1000633.
Garcia-Exposito L, Barroso-Gonzalez J, Puigdomenech I, Machado JD, Blanco J, Valenzuela-Fernandez A: HIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes. Mol Biol Cell. 2011, 22: 1148-1166. 10.1091/mbc.E10-08-0722.
Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV: Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol. 2002, 76: 11440-11446. 10.1128/JVI.76.22.11440-11446.2002.
Schaeffer E, Soros VB, Greene WC: Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol. 2004, 78: 1375-1383. 10.1128/JVI.78.3.1375-1383.2004.
Daecke J, Fackler OT, Dittmar MT, Krausslich HG: Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol. 2005, 79: 1581-1594. 10.1128/JVI.79.3.1581-1594.2005.
von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, MacGregor KA, Tomlin N, Pechstein A, Chau N, Chircop M, Sakoff J, von Kries JP, Saenger W, Krausslich HG, Shupliakov O, Robinson PJ, McCluskey A, Haucke V: Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell. 2011, 146: 471-484. 10.1016/j.cell.2011.06.025.
Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T: Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006, 10: 839-850. 10.1016/j.devcel.2006.04.002.
Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB: HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell. 2009, 137: 433-444. 10.1016/j.cell.2009.02.046.
Permanyer M, Ballana E, Este JA: Endocytosis of HIV: anything goes. Trends Microbiol. 2010, 18: 543-551. 10.1016/j.tim.2010.09.003.
Miyauchi K, Marin M, Melikyan GB: Visualization of retrovirus uptake and delivery into acidic endosomes. Biochem J. 2011, 434: 559-569. 10.1042/BJ20101588.
Markosyan RM, Cohen FS, Melikyan GB: Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell. 2005, 16: 5502-5513. 10.1091/mbc.E05-06-0496.
Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M: Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry. 2007, 46: 4360-4369. 10.1021/bi7001289.
Chan DC, Kim PS: HIV entry and its inhibition. Cell. 1998, 93: 681-684. 10.1016/S0092-8674(00)81430-0.
Markosyan RM, Cohen FS, Melikyan GB: HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell. 2003, 14: 926-938. 10.1091/mbc.E02-09-0573.
Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS: Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol. 2000, 151: 413-424. 10.1083/jcb.151.2.413.
Kliger Y, Shai Y: Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol. 2000, 295: 163-168. 10.1006/jmbi.1999.3368.
Cavrois M, De Noronha C, Greene WC: A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002, 20: 1151-1154. 10.1038/nbt745.
Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997, 71: 7478-7487.
Melikyan GB, Barnard RJ, Abrahamyan LG, Mothes W, Young JA: Imaging individual retroviral fusion events: from hemifusion to pore formation and growth. Proc Natl Acad Sci USA. 2005, 102: 8728-8733. 10.1073/pnas.0501864102.
Henderson HI, Hope TJ: The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection. Virol J. 2006, 3: 36-10.1186/1743-422X-3-36.
Mkrtchyan SR, Markosyan RM, Eadon MT, Moore JP, Melikyan GB, Cohen FS: Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol. 2005, 79: 11161-11169. 10.1128/JVI.79.17.11161-11169.2005.
Blumenthal R, Clague MJ, Durell SR, Epand RM: Membrane fusion. Chem Rev. 2003, 103: 53-69. 10.1021/cr000036+.
Cheetham JJ, Epand RM, Andrews M, Flanagan TD: Cholesterol sulfate inhibits the fusion of Sendai virus to biological and model membranes. J Biol Chem. 1990, 265: 12404-12409.
St.Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NA, Epand R, Epand R, Khramyshev SS, Valueva OA, Korshun VA, Tyrrell DLJ, Schang LM: Rigid Amphipathic Fusion Inhibitors, RAFIs, Small Molecule Antiviral Compounds Against Enveloped Viruses. Proc Natl Acad Sci USA. 2010
Yeagle PL, Young J, Hui SW, Epand RM: On the mechanism of inhibition of viral and vesicle membrane fusion by carbobenzoxy-D-phenylalanyl-L-phenylalanylglycine. Biochemistry. 1992, 31: 3177-3183. 10.1021/bi00127a019.
Epand RM: Lipid polymorphism and protein-lipid interactions. Biochim Biophys Acta. 1998, 1376: 353-368.
Epand RM: Membrane lipid polymorphism: relationship to bilayer properties and protein function. Methods Mol Biol. 2007, 400: 15-26. 10.1007/978-1-59745-519-0_2.
Role of Membrane Lipids in Modulating the Activity of Membrane-Bound Enzymes. Edited by: Epand RM. 2005, Boca Raton, FL: CRC Press
Epand RM: Diacylglycerols, lysolecithin, or hydrocarbons markedly alter the bilayer to hexagonal phase transition temperature of phosphatidylethanolamines. Biochemistry. 1985, 24: 7092-7095. 10.1021/bi00346a011.
Quan A, McGeachie AB, Keating DJ, van Dam EM, Rusak J, Chau N, Malladi CS, Chen C, McCluskey A, Cousin MA, Robinson PJ: Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin II. Mol Pharmacol. 2007, 72: 1425-1439. 10.1124/mol.107.034207.
Epand RM, Robinson KS, Andrews ME, Epand RF: Dependence of the bilayer to hexagonal phase transition on amphiphile chain length. Biochemistry. 1989, 28: 9398-9402. 10.1021/bi00450a022.
Marsh M, Helenius A: Virus entry: open sesame. Cell. 2006, 124: 729-740. 10.1016/j.cell.2006.02.007.
Mercer J, Schelhaas M, Helenius A: Virus entry by endocytosis. Annu Rev Biochem. 2010, 79: 803-833. 10.1146/annurev-biochem-060208-104626.
Beer C, Andersen DS, Rojek A, Pedersen L: Caveola-dependent endocytic entry of amphotropic murine leukemia virus. J Virol. 2005, 79: 10776-10787. 10.1128/JVI.79.16.10776-10787.2005.
Katen LJ, Januszeski MM, Anderson WF, Hasenkrug KJ, Evans LH: Infectious entry by amphotropic as well as ecotropic murine leukemia viruses occurs through an endocytic pathway. J Virol. 2001, 75: 5018-5026. 10.1128/JVI.75.11.5018-5026.2001.
Kolokoltsov AA, Deniger D, Fleming EH, Roberts NJ, Karpilow JM, Davey RA: Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus. J Virol. 2007, 81: 7786-7800. 10.1128/JVI.02780-06.
Guo J, Wang W, Yu D, Wu Y: Spinoculation triggers dynamic actin and cofilin activity that facilitates HIV-1 infection of transformed and resting CD4 T cells. J Virol. 2011, 85: 9824-9833. 10.1128/JVI.05170-11.
Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, Liu J, Wang W, Vorster PJ, Agulto L, Stephany DA, Cooper JN, Marsh JW, Wu Y: HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell. 2008, 134: 782-792. 10.1016/j.cell.2008.06.036.
Zhu P, Liu J, Bess J, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH: Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006, 441: 847-852. 10.1038/nature04817.
Kruchten AE, McNiven MA: Dynamin as a mover and pincher during cell migration and invasion. J Cell Sci. 2006, 119: 1683-1690. 10.1242/jcs.02963.
Schroeder B, Weller SG, Chen J, Billadeau D, McNiven MA: A Dyn2-CIN85 complex mediates degradative traffic of the EGFR by regulation of late endosomal budding. EMBO J. 2010, 29: 3039-3053. 10.1038/emboj.2010.190.
Nicoziani P, Vilhardt F, Llorente A, Hilout L, Courtoy PJ, Sandvig K, van Deurs B: Role for dynamin in late endosome dynamics and trafficking of the cation-independent mannose 6-phosphate receptor. Mol Biol Cell. 2000, 11: 481-495.
Robinet P, Fradagrada A, Monier MN, Marchetti M, Cogny A, Moatti N, Paul JL, Vedie B, Lamaze C: Dynamin is involved in endolysosomal cholesterol delivery to the endoplasmic reticulum: role in cholesterol homeostasis. Traffic. 2006, 7: 811-823. 10.1111/j.1600-0854.2006.00435.x.
Lauvrak SU, Torgersen ML, Sandvig K: Efficient endosome-to-Golgi transport of Shiga toxin is dependent on dynamin and clathrin. J Cell Sci. 2004, 117: 2321-2331. 10.1242/jcs.01081.
Engel S, Heger T, Mancini R, Herzog F, Kartenbeck J, Hayer A, Helenius A: Role of endosomes in simian virus 40 entry and infection. J Virol. 2011, 85: 4198-4211. 10.1128/JVI.02179-10.
Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002, 46: 1896-1905. 10.1128/AAC.46.6.1896-1905.2002.
Nara PL, Fischinger PJ: Quantitative infectivity assay for HIV-1 and-2. Nature. 1988, 332: 469-470. 10.1038/332469a0.
Trkola A, Matthews J, Gordon C, Ketas T, Moore JP: A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol. 1999, 73: 8966-8974.
Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, Reitz MS: Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995, 69: 3712-3720.
Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR: Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol. 2003, 77: 5678-5684. 10.1128/JVI.77.10.5678-5684.2003.
Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R: Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol. 2006, 80: 1414-1426. 10.1128/JVI.80.3.1414-1426.2006.
Tobiume M, Lineberger JE, Lundquist CA, Miller MD, Aiken C: Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol. 2003, 77: 10645-10650. 10.1128/JVI.77.19.10645-10650.2003.
Sherer NM, Lehmann MJ, Jimenez-Soto LF, Ingmundson A, Horner SM, Cicchetti G, Allen PG, Pypaert M, Cunningham JM, Mothes W: Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic. 2003, 4: 785-801. 10.1034/j.1600-0854.2003.00135.x.
Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA. 2003, 100: 11013-11018. 10.1073/pnas.1832214100.
Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schon A, Phan N, Wang L, Biorn AC, Cocklin S, Chaiken I, Freire E, Smith AB, Sodroski JG: Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA. 2004, 101: 5036-5041. 10.1073/pnas.0307953101.
Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998, 4: 72-77. 10.1038/nm0198-072.
Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA. 2002, 99: 395-400. 10.1073/pnas.012519099.
Andrawiss M, Takeuchi Y, Hewlett L, Collins M: Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association. J Virol. 2003, 77: 11651-11660. 10.1128/JVI.77.21.11651-11660.2003.
Malim MH, Hauber J, Fenrick R, Cullen BR: Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature. 1988, 335: 181-183. 10.1038/335181a0.
Kimpton J, Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol. 1992, 66: 2232-2239.
The authors wish to thank Dr. Min Lu for the gift of the C52L peptide, Dr. J. Strizki for providing AD101, and the members of the Melikyan lab for helpful discussions. This work was supported by the NIH R01 GM054787 grant to G.B.M. and by the Canadian Institutes for Health Research (grant MOP 86608) to RME.
The authors declare that they have no competing interests.
MD, MM, NK, KM, YK and RFE performed the experiments and analyzed the data. GBM conceived and planned the experiments and co-wrote the manuscript with MD and MM. RFE and RME co-wrote the manuscript and analyzed the data. All authors read and approved the final manuscript.
Michelle de la Vega, Mariana Marin contributed equally to this work.
Electronic supplementary material
Additional file 1: Figure S1. Dynasore, but not dynole or MiTMAB, quenches the fluorescence of lipophilic dyes. (A) HXB2 pseudotyped viruses co-labeled with Gag-mKO/DiD (upper panel) or Gag-mKO/DiO (lower panel, DiO is colored red) were adhered to poly-L-lysine coated coverslips. Sixty μM of dynasore (Santa Cruz) in HBSS++ was added 1 min after beginning the image acquisition. Scale bar is 20 μm. (B) Mean fluorescence from co-labeled viruses (at least 100 particles per image field) was calculated and plotted over time. Dashed line shows the change in the DiD signal in another experiment when the compound was removed by washing. (C) HXB2 pseudoviruses co-labeled with Gag-GFP and R18 (C, D) or DiD (E-G) were adhered to poly-lysine coated chambered coverslips and imaged in HBSS++ for 5 min at room temperature. Sixty μM of dynasore (C, D), 80 μM of MiTMAB (E, F) or 60 μM of dynole 34-2 (G) in HBSS++ was added at the 1 min point (arrows). At least 100 co-labeled viruses were analyzed for changes in the mean fluorescence intensity of GFP, mKO, DiD and R18 over time. (PDF 306 KB)
Additional file 2: Figure S2. Transferrin uptake is blocked by dynasore and partially inhibited by dynole. TZM-bl cells were left untreated (A, B) or were pretreated with 80 μM dynasore from different manufacturers (C-G), dynole 34-2 (H) or with dynole 31-2 (inactive control, I) dissolved in DMEM for 30 min at 4°C or 37°C. Cells were then incubated with 20 μg/ml of transferrin-Alexa488 (Invitrogen) in the cold, washed and further incubated for 10 min at 4°C (black histogram) or at 37°C (red line) in the absence or in the presence of dynamin inhibitors. Residual transferrin-Alexa488 at the cell surface was removed by pronase treatment (2 mg/ml, 10 min on ice), cells were washed with cold PBS supplemented with 10% FBS and resuspended in an appropriate volume of cold PBS. Transferring uptake was measured by flow cytometry (FACS LSRII, BD Biosciences) gating on live cells negative for the propidium iodide staining. (PDF 228 KB)
Additional file 3: Figure S3. Dynole, but not dynasore, affects the cell viability at concentrations that inhibit transferrin endocytosis. (A) The dose-dependent effect of dynasore from different manufacturers on TZM-bl cell viability was as determined by the MTS assay, using CellTiter 96 Aqueous reagent (Promega) according to the manufacturer's specifications. The resulting absorbance measured at 490 nm in triplicate wells was normalized to the signal from untreated cells. Error bars are SEM. (B) The effect of dynole 34-2 and dynole 31-2 (inactive compound) from Ascent on TZM-bl cell viability determined by the MTS assay. (PDF 37 KB)
Additional file 4: Figure S4. The effect of dynole on the uptake of HIV-1 pseudoviruses. Representative images of HXB2 pseudovirus uptake by TZM-bl cells are shown. Cells were pretreated with 60 μM dynole 34-2 (A) or with 60 μM dynole 31-2 (inactive compound) (B) in HBSS++ for 30 min followed by binding of pseudoviruses co-labeled with HIV Gag-Cherry and EcpH-ICAM-1 (a chimera consisting of the Ecliptic pHluorin and the ICAM-1 transmembrane domain [23, 25]). Cells were washed to remove unbound viruses and either imaged immediately (0 min) or incubated for 60 min at 37°C (60 min) in the presence of a dynamin inhibitor, using the Zeiss LSM780 confocal microscope. Scale bar is 20 μm. (C) Quantification of pseudovirus uptake exemplified in panels A and B. Z-stacks of cells from at least 5 random areas were acquired. Virus entry into acidic endosomes upon incubation at 37°C was manifested by quenching of the EcpH fluorescence (green) while the signal from mCherry-tagged viral cores (red) was not significantly altered. The total EcpH intensity from several hundreds of cell-associated double-labeled viruses was determined, and the ratio of the sum of EcpH signal to the sum of mCherry signal (normalized to that at time = 0) was plotted. (PDF 190 KB)
Additional file 5: Movie 1. Dynasore does not affect HXB2 virus motility. HXB2 pseudoviruses co-labeled with Gag-mKO (green) and DiD (red) were bound to TZM-bl cells at 4°C, and cells were transferred to 37°C to initiate fusion, at which point the and imaging begun. After 5 min, 60 μM dynasore (Santa Cruz) was added to cells, and acquisition continued for an additional 15 min. Images were acquired using the Personal DeltaVision system. (QT 1 MB)
Additional file 6: Movie 2. Rab5 motility is not altered by dynasore treatment. TZM-bl cells were transfected with Rab5-GFP. Twenty four hours after transfection, cells were imaged at 37°C. After 5 min, 60 μM of dynasore (Santa Cruz) was introduced and imaging was continued for additional 15 min. Images were acquired using the Personal DeltaVision system and processed with the Spot Enhancing Filter 2D plugin from ImageJ. (QT 1 MB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
- HIV fusion kinetics
- fusion pore
- temperature-arrested intermediate
- fusion inhibitors
- single particle tracking
- intrinsic membrane curvature